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BACKGROUND: Cerebellar mutism syndrome (CMS) is the common-
est and most serious complication of posterior fossa tumour surgery with 
life-long consequences on speech and motor function. Despite previous 
identification of pre-operative clinical and radiological predictors of 
CMS, a unifying pre-operative risk stratification model for use during sur-
gical consent is currently lacking. The aims of the project are to develop 
a simple pre-operative risk scoring scheme to stratify patients in terms 
of post-operative CMS risk. METHODS: Pre-operative radiological fea-
tures were recorded for a retrospectively assembled cohort of 89 posterior 
fossa tumor patients from two major UK treatment centers (age 2-23yrs; 
gender 28M,61F; diagnosis: 38 pilocytic astrocytoma, 32 medulloblas-
toma, 12 ependymoma, 1 high grade glioma, 1 pilomyxoid astrocytoma, 
1 atypical teratoid rhabdoid tumor, 1 hemangioma, 1 neurilemmoma, 2 
oligodendroglioma). Twenty-six (29%) developed post-operative CMS. 
Based upon results from univariate analysis and C4.5 decision tree, step-
wise logistic regression was used to develop the optimal model and gener-
ate risk scores. RESULTS: Univariate analysis identified five significant 
risks and C4.5 decision tree identified six predictors. The final model has 
an accuracy of 88.8% (79/89). Using risk score cut-off of 203 and 238 
allowed discrimination into low (38/89, predicted CMS probability < 
3%), intermediate (17/89, predicted CMS probability 3–52%) and high-
risk (34/89, predicted CMS probability ≥ 52%). CONCLUSIONS: We will 
continue to work with leading neurosurgical centres in Europe and North 
America to expand the cohort and organise an international workshop 
in Nottingham to (1) validate and/or modify the preliminary model; (2) 
compare surgical techniques through detailed discussion; and (3) use the 
information exchange to establish a stratified approach to cerebellar mut-
ism risk reduction. Following further multi-centre validation, this tool 
could be of value in providing CMS risk during the consent procedure 
and for stratifying patients in terms of CMS risk in trials of therapeutic 
strategies.
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BACKGROUND: Public and professional concern about delays in diag-
nosis of childhood brain tumours has led to a clinical referral guidelines and 
the HeadSmart campaign to raise awareness of the early features of brain 
tumours and the need for timely imaging. As part of the outcome evalua-
tion, we have collected data on total diagnostic intervals (TDI) i.e. intervals 
between symptom onset to diagnosis through a national service evaluation. 
The aims of the project are to (1) report the most recent TDI; and (2) identify 
the subgroup(s) with the longest symptom interval. METHODS: Paediatric 
brain tumour cases (aged 0–18  years) diagnosed between June 2014 and 
May 2015 were identified through a network of HeadSmart clinical cham-
pions. Age at diagnosis, dates of first symptom onset, first presentation to 
healthcare and diagnosis, tumour site, diagnosis were collected thorough 
an online data collection form. RESULTS: Data of 334 eligible cases, rep-
resenting over 75% of incident cases in the UK of that year were recorded. 
TDI showed a right skewed distribution with a 90th percentile of 48 weeks 
and maximum of 313 weeks. Group median TDI had reduced significantly 
from 14.4 weeks in 2006, to 9.1 weeks in 2011 at the time HeadSmart was 
launched, and then to 6.5 weeks in 2015. Stratified analysis showed that 
there is still a significant difference between age groups. Median TDI is 3.9, 
6.6 and 9.9 weeks for children under 5, 5–11 years and 12–18, respectively. 
CONCLUSIONS: These findings justifying a more targeted approach for the 
awareness campaign. With a rebranded website (www.headsmart.org.uk), 
new animation, posters to summarise symptom by subspecialty and quick 
reference guide, we hope to raise the awareness amongst young people aged 
12–18 years and general practitioners, and reduce the median TDI further to 
national target of four weeks.
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& Tropical Medicine, London, UK, 3Moorfields Eye Hospital NHS 
Foundation Trust, London, UK.
INTRODUCTION: Vision loss occurs in children with brain tumour due 
to prolonged pre-diagnostic raised intra-cranial pressure or by direct involve-
ment of visual pathway structures. The HeadSmart campaign was launched 
in 2011 to disseminate national referral guidelines for brain tumor diagno-
sis, published in 2008 and demonstrated to be associated with a reduction 
in Total Diagnostic Interval (TDI) from 13.4 weeks in 2006 to 6.7 weeks in 
2014. METHODS: Records of patients with brain tumor diagnosed aged 
0–24  years from the National Cancer Registry (1997–2012, n  =  19,555) 
were probabilistically linked to 13,013 national records of the electronic 
Certificate of Visual Impairment (eCVI, 2007–2012), to identify 336 brain 
tumor patients with registered partial or complete vision loss. Variation in 
the risk of vision loss associated with different tumor location and histology 
was estimated. In this cohort CNS neoplasm, optic atrophy and multiple 
causes accounted for 36%, 17.5% and 15.3%, respectively, of eCVI certifi-
cations. RESULTS: Overall, vision loss occurred in 3.7% of childhood brain 
tumor patients up to two years after diagnosis. The risk was greatest (6.0%) 
in 0–5 year-olds and lowest (1.5%) in 19–25 year-olds. Tumours above the 
tentorium (5.1%), cranial nerve (4.5%) and in the midline (4.2%) pose the 
highest risk. Pilocytic astrocytomas, choroid plexus tumors, sellar tumors, 
nerve sheath tumors and pineal tumors were also strongly associated with 
vision loss. eCVI registrations fell from 5.8% in 2007 to 3.5% in 2011. 
CONCLUSIONS: Brain tumour was the commonest cause of blindness cer-
tification, affecting 6% of children aged <5 years, it was most common in 
benign / slow growing tumors affecting midline structures. The proportion 
with blindness certification has fallen between 2007–2012, coinciding with 
the reduction in reported TDI since the launch of referral guideline, which 
was the focus of the subsequent HeadSmart campaign. Certifications data 
provided by the Certifications Office (The Royal College of Ophthalmolo-
gists, c/o Certifications Office, Moorfields Eye Hospital), captured by the 
Certificate of Vision impairment (CVI) are Department of Health copyright 
and this work was made possible by collaboration with the Royal College 
of Ophthalmologists. Any views expressed in the publication are those of 
the author(s) alone and not necessarily those of the Department of Health.
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BACKGROUND: Histone deacetylases (HDACs) are crucial regulators 
of epigenetic and posttranslational modifications and therefore represent a 
promising therapeutic target in cancer cells that harbor distinct epigenomes 
from normal cells. To exploit the therapeutic potential of HDAC inhibitors 
(HDACi) we synthesized a unique in-house library of more than 200 inhibi-
tors. For the evaluation of the antitumor effects of the compound library 
in brain tumor cell lines, we successfully established an optimal screen-
ing workflow. METHODS: The screening procedure was streamlined by 
automated dispensing of cell lines, reagents and inhibitors using state of 
the art equipment. The drugs were evaluated for their effect on tumor cell 
viability in a panel of cell lines derived from different brain tumor enti-
ties (8 glioblastoma, 10 medulloblastoma and 6 atypical teratoid/rhabdoid 
tumor cell lines) and compared to 5 normal control tissues. Correspond-
ing dose-response profiles were generated using an optimized bioinformat-
ics workflow. In addition to our in-house library commercially available 
and clinically used HDACi (e.g. Vorinostat) were included. RESULTS: The 
semi-automated setup enabled the miniaturization of the assay format to 
384-well plates. In combination with additional modifications, a remarkable 
increase of the overall throughput was realized, while generating accurate 
and reproducible results. Based on this workflow, we created a unique and 
comprehensive data set and could thereby identify various HDACi acting 
universally across brain tumors or being specifically active in distinct tumor 
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/19/suppl_4/iv57/3859535 by London School of H
ygiene & Tropical M
edicine user on 11 D
ecem
ber 2019
